Nervous System & Special Senses

Idiopathic intracranial hypertension: diagnosis and management

Clinical Overview and When to Suspect Idiopathic Intracranial Hypertension

— Overwhelmingly affects obese women of childbearing age (90%+); incidence ~20/100,000 in obese women 20–44 vs ~1/100,000 general population.

— Strongly correlated with recent weight gain (even 5–15% above baseline).

— Impaired CSF absorption at arachnoid granulations and/or cerebral venous sinus stenosis (transverse sinus) generating an outflow gradient.

— Elevated intra-abdominal/intrathoracic pressure from obesity raises central venous pressure → decreased CSF reabsorption.

— Daily headache (often retro-orbital, worse with Valsalva, recumbency, morning)

— Transient visual obscurations (seconds-long graying with postural change or Valsalva)

— Pulsatile tinnitus ("whooshing" synchronous with pulse, often unilateral)

— Young obese woman + papilledema on routine eye exam

— Recent initiation of tetracyclines (doxycycline, minocycline), vitamin A/retinoids (isotretinoin), growth hormone, or stopping chronic steroids

— New-onset diplopia from CN VI palsy (false localizing sign of elevated ICP)

Board pearl: When a stem describes an obese 28-year-old woman with daily headaches, pulsatile tinnitus, and blurred vision on standing, think IIH first — order brain MRI with MR venography, then lumbar puncture with opening pressure, then urgent formal ophthalmology with perimetry. The visual field, not the headache severity, dictates management aggressiveness.

Definition: Syndrome of elevated intracranial pressure (ICP) without structural, vascular, or infectious cause, with normal CSF composition — formerly "pseudotumor cerebri."

Epidemiology:

Pathophysiology (working model):

Classic triad to suspect:

Red-flag triggers that should raise IIH on Step 3 stems:

Why this matters: Untreated IIH causes permanent vision loss in up to 25% — vision, not headache, drives urgency of workup and treatment.

Presentation Patterns and Key History

— Daily, progressive over weeks–months; often described as pressure-like or throbbing.

— Worse with Valsalva, bending, lying flat, early morning — features shared with any raised-ICP syndrome.

— May meet migraine phenotype (photophobia, nausea) → easy to misdiagnose as chronic migraine.

— Transient visual obscurations (TVOs): brief (<30 sec) graying or blacking out of vision, often with posture change or Valsalva; reflects optic nerve head ischemia from papilledema.

— Progressive peripheral field loss (nasal inferior quadrant first) — patient may not notice until central acuity threatened.

— Horizontal diplopia from unilateral or bilateral CN VI palsy (stretched over petrous ridge by downward brain displacement).

— Sustained blurred vision or color desaturation = late, urgent finding.

— Weight trajectory: recent gain of even 5–10% is a major trigger.

— Medication review (high-yield):

— Tetracyclines: doxycycline, minocycline, tetracycline

— Vitamin A excess / retinoids: isotretinoin, all-trans retinoic acid

— Growth hormone, levothyroxine in children

— Recent glucocorticoid taper or withdrawal

— Lithium, nalidixic acid (less common)

— OSA screening (STOP-BANG): comorbid sleep apnea worsens IIH.

— PCOS, recent pregnancy, OCP use.

— Focal weakness, seizures, encephalopathy, fever → search for another diagnosis.

— Cognitive decline, ataxia → consider hydrocephalus, mass, infection.

Key distinction: IIH headache phenotype overlaps heavily with chronic migraine — the differentiator is papilledema on exam. Any obese young woman labeled "chronic migraine" who hasn't had a recent dilated fundoscopic exam should get one before escalating migraine prophylaxis.

Headache (>90%):

Visual symptoms — the prognostic core:

Pulsatile tinnitus (~60%): Whooshing heartbeat sound, often relieved by jugular compression or head turn — reflects turbulent flow in stenotic transverse sinus.

Neck/back pain and radicular symptoms: From elevated spinal CSF pressure.

Critical history to extract on Step 3 stems:

What is NOT typical for IIH:

Physical Exam Findings and Neuro-Ophthalmic Assessment

— Document BMI, blood pressure (rule out malignant hypertension as papilledema mimic), neck circumference.

— Skin: acne, hirsutism (PCOS association); striae from rapid weight gain or exogenous steroids.

— Bilateral papilledema: blurred disc margins, elevated disc, obscured vessels at the disc edge, peripapillary hemorrhages, cotton-wool spots in severe cases.

— Use the Frisén scale (0–5) to grade severity; grade ≥3 or any hemorrhages raises urgency.

— Spontaneous venous pulsations, when present, suggest ICP <200 mm H₂O (absence is nonspecific — 10% of normals lack them).

— Visual acuity each eye, color plates (Ishihara) — desaturation = optic nerve dysfunction.

— Confrontation fields are insensitive; formal perimetry is required.

— Relative afferent pupillary defect (RAPD) suggests asymmetric optic neuropathy — late finding.

— CN VI palsy (uni- or bilateral) → horizontal diplopia, esotropia, impaired abduction. False localizing sign, not a focal lesion.

— Other focal cranial nerve deficits should prompt alternative diagnosis (e.g., cavernous sinus pathology, meningitis).

— Automated perimetry (Humphrey 24-2 or 30-2) to quantify field loss — repeat at every visit.

— OCT of retinal nerve fiber layer (RNFL) to objectively track papilledema thickness.

— Fundus photography for serial comparison.

Step 3 management: On a CCS case, the order set after suspecting IIH should include "ophthalmology consult, urgent" with visual fields and OCT — these data points, more than headache or opening pressure, determine whether you proceed medically or escalate to surgery.

General exam:

Fundoscopy — the cornerstone:

Visual function bedside:

Cranial nerves:

Rest of neuro exam: Should be otherwise normal. Strength, sensation, reflexes, gait, mental status intact. Any focal deficit = not pure IIH.

Formal ophthalmology referral — required at diagnosis:

Diagnostic Workup — Initial Imaging and Laboratory Studies

— Purpose: exclude mass, hydrocephalus, venous sinus thrombosis, meningeal disease.

— Indirect signs supporting IIH (none are required for diagnosis):

— Empty sella (flattened pituitary)

— Posterior globe flattening and protrusion of optic nerve head

— Distended optic nerve sheaths with perineural CSF

— Vertical tortuosity of optic nerves

— Slit-like ventricles (less common)

— Excludes cerebral venous sinus thrombosis (CVST), which can mimic IIH exactly.

— May reveal bilateral transverse sinus stenosis — common in IIH and now considered part of the disease, not exclusionary.

— CBC, CMP, TSH

— In selected patients: ESR/CRP, ANA (lupus/CNS vasculitis), HIV, RPR, Lyme

— Hypercoagulable workup if MRV suggests CVST (factor V Leiden, prothrombin gene, antiphospholipid antibodies, protein C/S)

— Pregnancy test in any reproductive-age woman before imaging contrast and medications

— Patient in lateral decubitus position with legs extended (not flexed — flexion falsely elevates opening pressure).

— Opening pressure measurement is the diagnostic anchor.

— Send CSF for: cell count, protein, glucose, Gram stain/culture, cytology if any atypical features.

Board pearl: Bilateral transverse sinus stenosis on MRV does not exclude IIH — it is found in the majority of patients and is increasingly targeted by venous sinus stenting in refractory disease. What you must exclude is dural venous sinus thrombosis (filling defect, "empty delta sign" on post-contrast imaging), because anticoagulation, not acetazolamide, is the treatment.

Imaging first, then LP — always. Performing LP before imaging risks herniation if a mass lesion is present.

Brain MRI with and without contrast — first-line:

MR venography (MRV) — mandatory:

CT venogram if MRI/MRV contraindicated (pacemaker, claustrophobia).

Laboratory workup — to exclude mimics and secondary causes:

Lumbar puncture — performed AFTER neuroimaging excludes mass/CVST:

Diagnostic Workup — Lumbar Puncture and Modified Dandy Criteria

— Adults: >250 mm H₂O (or >280 mm H₂O in obese patients, per some experts) supports diagnosis.

— Children: >280 mm H₂O (or >250 if non-obese and non-sedated).

— Must be measured in lateral decubitus with relaxed, extended legs.

— Normal cell count (<5 WBC), normal protein, normal glucose.

— Abnormal CSF → search for meningitis, carcinomatosis, inflammatory disease.

— Signs/symptoms of elevated ICP (headache, papilledema, TVOs)

— No localizing neurologic signs except CN VI palsy

— Normal CSF composition

— Elevated opening pressure on LP

— Normal neuroimaging (no mass, hydrocephalus, structural cause; venous sinus stenosis allowed)

— No other identified cause of intracranial hypertension

— Recognized subset; requires elevated OP plus other features (e.g., CN VI palsy, classic imaging signs) — diagnose cautiously and only after thorough mimic exclusion.

— Removing 20–30 mL CSF often transiently relieves headache — useful diagnostically but not durable therapy. Repeated serial LPs are no longer recommended.

— Falsely elevated OP from Valsalva, crying child, hyperventilation, or flexed legs.

— A single normal OP does not exclude IIH if clinical picture is strong — pressures fluctuate.

— Do not perform LP if imaging shows mass effect, midline shift, or obstructive hydrocephalus.

Key distinction: IIH = elevated ICP + normal CSF composition + normal parenchymal imaging. If CSF has pleocytosis or elevated protein, the diagnosis is not IIH — pivot to meningitis (infectious, neoplastic, inflammatory) or CVST regardless of how classic the demographic looks.

Opening pressure (OP) thresholds:

CSF composition — must be normal:

Modified Dandy Criteria (diagnosis of IIH):

"IIH without papilledema" (IIHWOP):

Therapeutic component of LP:

Pitfalls to avoid on Step 3 stems:

Risk Stratification and Treatment Decision Logic

— Normal acuity, minimal field loss (mean deviation > –7 dB), papilledema Frisén ≤2

— Management: weight loss + acetazolamide; outpatient follow-up.

— Moderate field loss, progressive papilledema, persistent symptoms despite first-line therapy

— Management: maximize acetazolamide (up to 4 g/day if tolerated), add topiramate or furosemide, intensify weight loss; consider bariatric referral.

— Rapid (<4 weeks) progression of vision loss, severe field defects (MD < –15 dB), decreased acuity, Frisén 4–5, macular involvement

— Step 3 management: admit, urgent neurosurgery and neuro-ophthalmology consults, IV acetazolamide, and proceed to CSF diversion (VP/LP shunt) or optic nerve sheath fenestration (ONSF) within days, not weeks.

— Weight loss: even 6–10% body weight reduction can induce remission. First-line for every patient.

— Acetazolamide: carbonic anhydrase inhibitor reduces CSF production; proven in IIHTT trial to improve visual fields.

— Avoid offending medications: stop tetracyclines, retinoids, exogenous vitamin A.

— Treat comorbid OSA aggressively (CPAP).

— Once ICP controlled, residual headache often requires migraine-type prophylaxis (topiramate doubles as IIH agent; avoid drugs that promote weight gain like amitriptyline, valproate).

— Low-sodium diet (modest evidence), graded exercise, sleep hygiene.

— Bariatric surgery referral for BMI ≥35 with refractory disease or BMI ≥40.

Board pearl: Sustained, structured weight loss is the only intervention that durably alters IIH natural history. Acetazolamide bridges the gap until weight is lost. In a CCS case, "nutrition consult" and "weight management referral" should appear on the order list alongside acetazolamide — leaving them off is a common omission penalty.

Treatment intensity is driven by vision, not headache. Stratify every patient by formal visual field severity at diagnosis and at follow-up.

Mild IIH:

Moderate IIH:

Severe / fulminant IIH:

Core therapeutic pillars (all severities):

Headache-only management:

Lifestyle counseling:

Pharmacotherapy — First-Line and Adjunctive Agents

— Start 500 mg PO BID, titrate by 250–500 mg increments weekly to symptom/field response; typical effective dose 1–2 g/day, max 4 g/day.

— Evidence: IIHTT (Idiopathic Intracranial Hypertension Treatment Trial) — acetazolamide + low-sodium weight-loss diet improved perimetric mean deviation vs diet alone.

— Mechanism: inhibits choroid plexus carbonic anhydrase → ↓ CSF production by ~50%.

— Adverse effects to counsel on:

— Paresthesias (fingers, toes, perioral) — most common, dose-related

— Dysgeusia (metallic taste, carbonated drinks taste flat)

— Fatigue, anorexia (mild weight loss — therapeutic bonus)

— Metabolic acidosis (non-anion gap) — monitor bicarb

— Hypokalemia, nephrolithiasis (calcium phosphate stones)

— Rare: aplastic anemia, Stevens-Johnson (sulfonamide allergy — relative contraindication)

— Monitoring: baseline and periodic BMP for bicarb, potassium, creatinine.

— 25 mg nightly, titrate to 100–200 mg/day in divided doses.

— Weak carbonic anhydrase activity + migraine prophylactic benefit + appetite suppression → ideal in IIH patients needing weight loss and headache control.

— Adverse effects: cognitive slowing ("dopamax"), word-finding difficulty, paresthesias, nephrolithiasis, teratogenic (cleft lip/palate) — counsel on contraception.

— 20–40 mg/day, often combined with acetazolamide in refractory cases.

— Monitor potassium and renal function; supplement K+ as needed.

— Tetracyclines, retinoids, vitamin A excess, growth hormone (if non-essential), lithium when feasible.

— Avoid weight-promoting drugs: amitriptyline, gabapentin (high doses), valproate, propranolol can be used but watch weight.

Step 3 management: Document a sulfa allergy history before prescribing acetazolamide. True sulfonamide antibiotic allergy is not an absolute contraindication to acetazolamide (different sulfonamide subclass), but stems often expect cautious counseling and shared decision-making.

Acetazolamide — first-line:

Topiramate — second-line or adjunct:

Furosemide:

Avoid or discontinue:

Glucocorticoids: Not for chronic use. Short bursts only in fulminant IIH as a bridge to surgery — rebound on withdrawal can precipitate IIH itself.

GLP-1 agonists / weight-loss pharmacotherapy: Emerging adjunct via weight reduction; reasonable in appropriate candidates.

Procedural and Surgical Management

— Fulminant IIH with rapid visual decline

— Progressive visual field loss despite maximally tolerated medical therapy

— Intractable headache unresponsive to medical management (relative indication)

— Medication intolerance

— Surgical slits in optic nerve dural sheath release perineural CSF pressure.

— Best for: vision-predominant disease without severe headache.

— Pros: protects vision, can be unilateral with bilateral benefit, lower morbidity than shunts.

— Cons: does not reliably treat headache; effect may diminish over years.

— Complications: transient diplopia, pupillary dysfunction, central retinal artery occlusion (rare), infection.

— Ventriculoperitoneal (VP) shunt preferred over lumboperitoneal (LP) shunt in current practice (lower revision rate, fewer pseudomeningoceles, better with stereotactic guidance for slit ventricles).

— Best for: headache-predominant disease and severe combined disease.

— Pros: rapid, robust ICP lowering, treats vision and headache.

— Cons: high revision rate (40–60% over 5 years), infection, obstruction, overdrainage with low-pressure headache, abdominal complications.

— Endovascular stent across stenotic transverse sinus when a trans-stenotic pressure gradient ≥8 mm Hg is documented.

— Emerging as effective alternative — improves headache, papilledema, and vision.

— Requires dual antiplatelet therapy peri-procedure.

— Risks: stent thrombosis, in-stent restenosis, intracranial hemorrhage (rare).

— Sleeve gastrectomy or Roux-en-Y for BMI ≥35 with refractory IIH or BMI ≥40.

— Produces durable remission in majority through sustained weight loss.

CCS pearl: In a fulminant IIH CCS case (rapid vision loss over days), the correct sequence is: admit → IV acetazolamide → urgent neuro-ophthalmology and neurosurgery consults → operative CSF diversion or ONSF within 24–72 hours. Waiting for medical optimization while vision deteriorates is the classic wrong answer.

Indications for surgical intervention:

Optic nerve sheath fenestration (ONSF):

CSF diversion — VP or LP shunt:

Venous sinus stenting (VSS):

Bariatric surgery:

Special Populations — Elderly, Renal, and Hepatic Considerations

— IIH is uncommon in this age group — strongly reconsider the diagnosis.

— Higher likelihood of secondary causes: dural venous sinus thrombosis, cerebral venous outflow obstruction from neck mass, sleep apnea, drug-induced.

— Lower likelihood of obesity-driven primary IIH.

— Workup expansion: thorough hypercoagulable evaluation, malignancy screen, careful medication reconciliation.

— Acetazolamide is renally cleared — dose adjustment required:

— CrCl 10–50 mL/min: extend interval (every 12 h → every 24 h), reduce dose.

— CrCl <10 mL/min: avoid.

— On dialysis: avoid or use under nephrology guidance.

— Increased risk of metabolic acidosis with renal impairment — monitor bicarb closely; consider oral bicarbonate supplementation.

— Furosemide: monitor for over-diuresis, electrolyte imbalance, AKI.

— Topiramate: renally cleared; reduce dose if CrCl <70 mL/min.

— Avoid acetazolamide in calcium phosphate stone formers without urology input.

— Acetazolamide: contraindicated in cirrhosis — alkaline urine promotes ammonia reabsorption → precipitates hepatic encephalopathy.

— Topiramate: hepatic metabolism partial; use cautiously; avoid in combination with valproate (hyperammonemia).

— Furosemide: hepatorenal syndrome risk; use cautiously in advanced cirrhosis.

— Patients on thiazides, ACE inhibitors, ARBs, or other diuretics: cumulative electrolyte effects with acetazolamide/furosemide.

— Hypokalemia from combined therapy can prolong QT — review baseline ECG in older patients or those on QT-prolonging drugs.

— Discontinue or substitute offending agents (tetracyclines, retinoids).

— Coordinate with primary care for HTN, DM, OSA — all common comorbidities in the IIH demographic.

Board pearl: A patient over 55 with "IIH" on a Step 3 stem should prompt aggressive search for an alternative diagnosis — cerebral venous sinus thrombosis, dural AV fistula, or paraneoplastic process is far more likely than primary IIH in this demographic.

Elderly patients (>55 years):

Renal impairment:

Hepatic impairment:

Cardiovascular/electrolyte considerations:

Polypharmacy review:

Special Populations — Pregnancy and Pediatrics

— IIH can present de novo or worsen in pregnancy, often early or mid-trimester, due to weight gain and fluid shifts.

— Visual prognosis is similar to non-pregnant patients when monitored — pregnancy itself is not a reason to terminate.

— Management:

— Weight gain restriction with obstetric and nutrition input.

— Serial LPs are an option for refractory symptoms but not preferred long-term.

— Acetazolamide: historically avoided in first trimester (animal teratogenicity, sacrococcygeal teratoma reports), but current evidence and consensus support use after 20 weeks when benefit outweighs risk; shared decision-making essential. Some experts allow earlier use with severe disease.

— Topiramate: contraindicated — clear teratogen (cleft lip/palate, hypospadias).

— Furosemide: category C; use with caution to avoid volume depletion.

— Surgery (ONSF, shunt) is feasible during pregnancy if vision threatened.

— Delivery: vaginal delivery is acceptable; second-stage Valsalva does not cause harm in well-controlled IIH. Epidural anesthesia is safe and does not worsen IIH.

— Monitor monthly with ophthalmology; field testing safe.

— Bimodal: pre-pubertal (no sex/BMI predilection) and post-pubertal (resembles adult pattern).

— Pre-pubertal IIH demands thorough secondary cause hunt: medications (growth hormone, retinoids, tetracyclines, levothyroxine initiation), recent steroid withdrawal, anemia, OSA, venous sinus thrombosis.

— Diagnostic OP threshold: >280 mm H₂O in children (or >250 if non-obese, non-sedated, relaxed).

— Management mirrors adults: acetazolamide first-line, dose 15–25 mg/kg/day divided BID-QID; weight loss for obese adolescents.

— Topiramate: avoid in young children due to cognitive effects.

— Acetazolamide is excreted in breast milk in low concentrations — generally considered compatible with breastfeeding.

Step 3 management: For a pregnant patient with new papilledema and headache, do brain MRI without contrast (gadolinium avoided unless essential), MRV (to exclude CVST — risk higher in pregnancy), then LP. Coordinate care among neurology, ophthalmology, MFM, and anesthesia early.

Pregnancy:

Pediatric IIH:

Postpartum and lactation:

Complications and Adverse Outcomes

— 10–25% of IIH patients suffer permanent visual deficit; 1–2% become legally blind.

— Predictors of poor visual outcome:

— Male sex (paradoxically worse prognosis despite lower incidence)

— Black race

— Severe papilledema at presentation (Frisén ≥4)

— High-grade visual field loss at diagnosis

— Fulminant course

— Anemia, OSA, uncontrolled hypertension as comorbidities

— Non-adherence with weight loss/medication

— Persists in >50% of patients even after ICP normalization.

— Frequently meets chronic migraine or medication-overuse headache criteria — requires dedicated headache management.

— Acetazolamide: metabolic acidosis, hypokalemia, nephrolithiasis, paresthesias, rare aplastic anemia/SJS.

— Topiramate: cognitive impairment, depression, kidney stones, glaucoma (acute angle closure — emergent), oligohidrosis with hyperthermia.

— Shunt complications:

— Mechanical failure/obstruction (most common reason for revision)

— Infection (early)

— Low-pressure headache from overdrainage — often more disabling than original headache

— Abdominal pseudocyst, distal catheter migration

— Subdural hematoma from overdrainage

— ONSF complications: orbital infection, diplopia, vascular injury.

— Venous stenting: stent thrombosis, in-stent stenosis, intracranial hemorrhage.

— Depression and anxiety prevalence elevated; chronic pain, vision threat, body-image issues compound.

— Lost productivity, disability claims common — address proactively.

— Rebound with weight regain or rapid steroid taper — counsel explicitly.

Key distinction: A shunted IIH patient who presents with new orthostatic headache (worse upright, better recumbent) likely has overdrainage/low-pressure headache — not recurrence. Imaging may show subdural collections or sagging midbrain. Management: shunt programmability adjustment, not more acetazolamide.

Permanent vision loss — the catastrophic outcome:

Chronic disabling headache:

Treatment complications:

Quality-of-life burden:

Recurrence:

When to Escalate Care — Inpatient and Consult Triggers

— Fulminant IIH — vision loss developing or progressing over days to weeks

— Severe papilledema (Frisén 4–5) with new visual field defects

— Decreased visual acuity (worse than 20/40 attributable to optic neuropathy)

— Severe new CN VI palsy with intractable headache

— Refractory headache requiring IV therapy

— Suspected fulminant course requiring expedited surgical planning

— Continuous neuro checks; bedside visual acuity and color vision Q4–6h

— Stat ophthalmology and neurosurgery consults

— IV acetazolamide (250–500 mg IV q6h) if PO not tolerable; or PO 500 mg BID titrated up

— Consider short-course IV methylprednisolone only as bridge to surgery (do not initiate steroids long-term)

— BMP daily, magnesium and phosphate, monitor for metabolic acidosis

— DVT prophylaxis (mechanical first; pharmacologic if not pre-op imminent)

— Low-sodium diet; consult nutrition

— New papilledema with normal acuity but moderate field loss

— New diagnosis pending workup

— Worsening symptoms on stable medical therapy

— Neuro-ophthalmology: quarterback of visual monitoring — fields, OCT, fundus photos

— Neurosurgery: CSF diversion candidacy

— Neurointerventional radiology: venous sinus stenting evaluation

— Bariatric surgery: durable weight loss

— Sleep medicine: OSA evaluation and CPAP

— MFM if pregnant

— Rare; reserved for fulminant IIH with imminent vision loss requiring aggressive IV therapy and same-day surgical intervention.

CCS pearl: When a CCS clock advances and serial OCT/visual fields show worsening despite maximal acetazolamide, the next correct order is "neurosurgery consult for CSF diversion" or "neuro-ophthalmology for optic nerve sheath fenestration" — not "increase acetazolamide further." Delay in escalation costs points and vision.

Admit to inpatient neurology or stroke unit when:

Initial inpatient orders (CCS-style):

Outpatient urgent referral (within 24–72 hours) when:

Consultant roles:

ICU consideration:

Key Differentials — Causes of Elevated ICP and Papilledema (Same Category)

— Presents identically to IIH (headache, papilledema, CN VI palsy, pulsatile tinnitus).

— Risk factors: pregnancy/postpartum, OCP, hypercoagulable states, dehydration, malignancy, head/neck infection.

— Diagnostic: filling defect on MRV/CTV, "empty delta sign."

— Treatment: anticoagulation — even with hemorrhagic infarction.

— Mass, aqueductal stenosis, Chiari malformation, colloid cyst → ventricular enlargement on imaging (absent in IIH).

— Requires CSF diversion targeted at the obstruction.

— Post-meningitic, post-hemorrhagic, neoplastic meningitis — abnormal CSF and/or imaging.

— Tumor, abscess, vascular malformation — focal deficits, mass effect, midline shift on imaging.

— Bacterial, TB, fungal, carcinomatous, or sarcoid meningitis — abnormal CSF (pleocytosis, ↑ protein, ↓ glucose, cytology positive).

— Pulsatile tinnitus, raised ICP from venous hypertension; angiography diagnostic.

— Orthostatic headache, opposite pattern — worse upright. MRI shows pachymeningeal enhancement, brain sagging. Treat with epidural blood patch.

— Hypertensive emergency causes papilledema (grade IV retinopathy) — BP measurement is key. Treat BP, not ICP.

— Drugs: tetracyclines, retinoids, vitamin A excess, growth hormone, lithium, nalidixic acid, recent steroid withdrawal

— Endocrine: Addison's, Cushing's withdrawal, hypoparathyroidism, hypothyroidism (children)

— Hematologic: severe anemia, polycythemia

— Renal failure

— Manage by removing/treating the cause; otherwise treat as IIH.

Key distinction: MRV is non-negotiable in any IIH workup. CVST shares the entire clinical phenotype but requires anticoagulation, not acetazolamide — getting this wrong on Step 3 is a high-stakes error.

Cerebral venous sinus thrombosis (CVST) — the must-not-miss mimic:

Obstructive hydrocephalus:

Communicating hydrocephalus:

Intracranial mass:

Meningeal disease:

Dural arteriovenous fistula:

Spontaneous intracranial hypotension (paradoxical mimic for chronic headache):

Malignant hypertension:

Secondary "pseudotumor" syndromes — distinguish from primary IIH:

Key Differentials — Headache and Vision Mimics (Other Category)

— Most commonly misdiagnosed in young women later found to have IIH.

— No papilledema, normal fundoscopy, normal OP on LP if done.

— Treated with standard migraine prophylaxis (topiramate, propranolol, CGRP antagonists).

— Daily analgesics (NSAIDs, triptans, opioids, butalbital) → rebound daily headache.

— Treatment: withdraw offending agent; bridge with naproxen or steroid taper.

— Unilateral, periorbital, autonomic features (lacrimation, rhinorrhea, ptosis), short attacks. Different demographic (M>F).

— Bilateral, band-like, no associated features; chronic forms common.

— Unilateral, painful vision loss with eye movement; central scotoma, RAPD, dyschromatopsia; disc usually normal initially (retrobulbar) but can have mild swelling.

— MRI shows optic nerve enhancement; oligoclonal bands suggest MS.

— Treat with high-dose IV methylprednisolone, plasma exchange if severe.

— Sudden painless monocular vision loss, altitudinal field defect, disc edema with hemorrhages.

— Arteritic AION (GCA): age >50, elevated ESR/CRP, jaw claudication, scalp tenderness — emergency steroids.

— Optic disc drusen mimic papilledema on exam but have buried calcifications visible on B-scan ultrasound or OCT; no field loss progression.

— Painful red eye, halos, fixed mid-dilated pupil, elevated IOP — emergency.

— Diagnosis of exclusion; normal exam, normal imaging, inconsistent fields.

Board pearl: Bilateral disc swelling = papilledema = elevated ICP until proven otherwise. Unilateral disc swelling is more likely optic neuritis, AION, or papillitis, not IIH. Confirm bilateral involvement before committing to the IIH pathway.

Chronic migraine:

Medication-overuse headache:

Cluster headache:

Tension-type headache:

Optic neuritis (e.g., MS, NMO, MOG):

Anterior ischemic optic neuropathy (AION):

Pseudopapilledema:

Acute angle-closure glaucoma:

Functional/psychogenic visual symptoms:

Secondary Prevention, Discharge Planning, and Long-Term Strategy

— Acetazolamide with titration plan and clear taper schedule when remission achieved

— Potassium supplementation if hypokalemic

— Adjunctive topiramate or furosemide if maximally tolerated acetazolamide insufficient

— Headache abortive plan (avoid opioids; triptans or NSAIDs PRN with overuse limits)

— Counsel against tetracyclines, retinoids, high-dose vitamin A

— If shunted: prophylactic plan for symptoms of shunt malfunction (sudden headache, vomiting, lethargy) — return to ED immediately

— Set explicit target: 6–10% body weight reduction

— Refer to nutritionist, structured weight-management program

— Bariatric surgery for BMI ≥35 with refractory disease or BMI ≥40

— Consider GLP-1 agonist (semaglutide, tirzepatide) where appropriate

— OSA: polysomnogram for all patients with BMI >30, snoring, or witnessed apneas; CPAP adherence improves ICP

— Hypertension control

— Diabetes/metabolic syndrome management

— Iron repletion if anemic (anemia worsens IIH)

— Annual influenza, COVID-19 updates

— Pneumococcal series per ACIP

— Cervical cancer, breast cancer screening per USPSTF — not to be neglected in chronic specialty care

— Especially with topiramate (teratogen, decreases OCP efficacy at >200 mg/day)

— Avoid weight-promoting hormonal methods if weight loss is the goal

— Pre-conception counseling re: medication changes, IIH activity, monitoring schedule

— Recognize warning symptoms: worsening headache, new transient visual obscurations, diplopia, decreasing vision

— Adherence to ophthalmology follow-up is the single most important behavior

Step 3 management: At discharge, document a structured follow-up calendar: ophthalmology in 2–4 weeks (then every 1–3 months until stable), neurology in 4–6 weeks, primary care for weight management within 2 weeks, sleep study referral if not already done. Care fragmentation is the most common reason for visual deterioration post-discharge.

Discharge medication checklist after new IIH diagnosis:

Weight loss program — the anchor:

Comorbidity optimization:

Vaccination and primary care:

Contraception counseling:

Reproductive planning:

Patient education:

Follow-Up, Monitoring, and Counseling

— Active disease / new diagnosis: every 2–4 weeks until stable

— Stable on medical therapy: every 1–3 months

— Remission: every 6–12 months for at least 2 years; lifetime if recurrent

— Each visit: visual acuity, color vision, formal automated perimetry, OCT RNFL, dilated fundus exam ± photography

— 4–6 weeks after diagnosis to assess symptom control and medication tolerance

— Then every 3–6 months until remission

— Coordinate headache phenotype management separately if ICP normalized but headaches persist

— BMP within 2–4 weeks of acetazolamide initiation, then every 3–6 months

— Bicarb <18 mEq/L → reduce dose or add bicarbonate supplementation

— Potassium <3.5 → supplement and reassess

— Topiramate: BMP, consider bicarbonate, mental status review

— Document weight every visit; share trajectory with patient

— Reinforce that weight regain is the primary cause of relapse

— Once weight loss target achieved and fields/OCT stable for 6+ months, taper slowly (250–500 mg decrements monthly) with ophthalmology checks before each dose reduction

— Driving: legal vision requirements vary by state; refer to DMV regulations when significant field loss exists

— Disability considerations: document objectively for accommodations

— Mental health: screen for depression with PHQ-9 at each visit — chronic headache and threatened vision are independent risk factors

— Pregnancy planning: preconception consultation, especially if on topiramate

— Avoid offending drugs for life — provide written list

— Annual imaging not routine; obtain when symptomatic

— Educate on signs of malfunction or infection — fever + headache requires urgent evaluation

CCS pearl: In a CCS office case, a follow-up visit for known IIH should always include orders for visual fields, OCT, BMP, and weight check. Missing any of the four is a common documentation gap and a frequent missed-point scenario.

Ophthalmology follow-up cadence (the spine of management):

Neurology follow-up:

Laboratory monitoring on therapy:

Weight monitoring:

Acetazolamide tapering:

Counseling specifics:

Shunt patients:

Ethical, Legal, and Patient Safety Considerations

— When recommending VP shunt vs ONSF vs venous stenting, present comparative benefits and risks honestly — shunts have ~50% 5-year revision rates; ONSF may not relieve headache; stenting requires antiplatelet therapy.

— Document shared decision-making in the chart.

— In fulminant cases requiring emergent surgery, document the time-sensitive nature of vision loss; if patient cannot consent (rare), proceed under emergency doctrine with two-physician documentation.

— Patients with significant field loss may not meet state driving vision standards — clinicians in some states (e.g., California) are mandated reporters of conditions impairing driving safety; know your state.

— Counsel pilots, commercial drivers, heavy-machinery operators about reporting to certifying authorities.

— Document the counseling explicitly.

— IIH care spans neurology, neuro-ophthalmology, neurosurgery, primary care, OB, bariatric surgery — hand-off failures cause vision loss.

— Use closed-loop referrals; ensure the patient has scheduled ophthalmology follow-up before leaving the hospital.

— Reconcile medications carefully — stopping acetazolamide for surgery without bridging is a common error.

— Sulfa allergy reconciliation before acetazolamide.

— Topiramate teratogenicity: document contraception counseling in any reproductive-age woman; failure to do so is a common malpractice and exam issue.

— Avoid prescribing offending agents (tetracyclines for acne, retinoids) — review pharmacy list at each visit.

— Discuss weight, contraception, and mental health in age-appropriate confidential settings consistent with state minor consent laws.

— IIH disproportionately affects women, often with lower socioeconomic status and limited bariatric access — actively coordinate insurance authorization and resource navigation.

— Objective field testing supports legitimate disability claims; provide accurate documentation when requested.

Board pearl: A pregnant patient with IIH on topiramate must be switched off topiramate prior to conception when possible due to cleft palate risk — failing to counsel on this is both a clinical error and an ethical/legal exposure routinely tested on Step 3.

Informed consent for surgical intervention:

Driving and occupational safety:

Transition-of-care risks (high-yield Step 3 concept):

Medication safety:

Adolescents and confidentiality:

Health equity considerations:

Disability documentation:

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: Papilledema (bilateral, from elevated ICP) vs papillitis (usually unilateral, painful, from optic neuritis) vs disc drusen (pseudopapilledema, no field progression, calcifications on OCT/ultrasound) — distinguishing these is the most common neuro-ophthalmology pivot on Step 3.

Demographics: Obese woman, 20–44 years, recent weight gain — almost a stereotype on the exam.

Triad: Headache + transient visual obscurations + pulsatile tinnitus.

Diagnostic anchor: Modified Dandy — papilledema + normal imaging + elevated OP + normal CSF.

Opening pressure threshold: >250 mm H₂O (adult); >280 in obese or children.

Imaging signs: Empty sella, posterior globe flattening, optic nerve sheath distension, transverse sinus stenosis.

Mandatory imaging study: MRV — to exclude CVST.

Vision is the prognostic driver, not headache.

First-line drug: Acetazolamide; IIHTT trial is the citation.

Second-line drug: Topiramate (bonus migraine effect, weight loss).

Cornerstone non-pharmacologic therapy: 6–10% weight loss.

Drugs that cause secondary "pseudotumor": tetracyclines, vitamin A/retinoids, growth hormone, lithium, steroid withdrawal.

Surgical options: VP shunt (headache + vision), ONSF (vision-predominant), venous sinus stenting (refractory with pressure gradient).

Worst prognosis features: male, Black race, anemia, fulminant onset, severe initial field loss.

CN VI palsy: false localizing sign of elevated ICP.

Pregnancy: can occur or worsen; vaginal delivery and epidural are safe.

Topiramate is teratogenic — cleft lip/palate.

Acetazolamide is contraindicated in cirrhosis (hepatic encephalopathy risk).

Slit ventricles on imaging are NOT required — ventricles are usually normal in IIH.

Pulsatile tinnitus localizes to transverse sinus stenosis.

Sleep apnea is undertreated in IIH — get a sleep study.

Bariatric surgery produces durable remission in refractory IIH.

Shunt failure rate: approximately 50% over 5 years.

Visual fields and OCT — the two follow-up tests that must appear on every visit.

IIH without papilledema (IIHWOP) exists but is a diagnosis of exclusion.

Anemia and IIH: correct iron deficiency — improves ICP.

Lateral decubitus required for accurate OP measurement.

Board Question Stem Patterns

— 27-year-old woman, BMI 36, 3 months of daily headache worse with bending, blurred vision when standing, "whooshing in my ear." Exam: bilateral disc edema. Next best step?

— Answer pathway: MRI brain + MRV first → then LP with opening pressure (lateral decubitus, legs extended) → if criteria met, start acetazolamide and refer to ophthalmology.

— 19-year-old on doxycycline for acne for 6 weeks now with daily headache and TVOs. Disc edema bilaterally.

— Answer: Stop the doxycycline + workup as above + acetazolamide.

— Postpartum woman on OCP with headache and papilledema. Stem may emphasize hypercoagulable risk.

— Answer: CVST until proven otherwise — get MRV; if filling defect → anticoagulate, not IIH treatment.

— Acuity dropping from 20/20 to 20/200 over 10 days, Frisén 5, severe field loss.

— Answer: Admit, IV acetazolamide, urgent CSF diversion or ONSF — not "increase oral acetazolamide and follow up in clinic."

— 28-week pregnant patient with known IIH, worsening field. Treatment?

— Answer: Acetazolamide is acceptable in second/third trimester; avoid topiramate (teratogen). Coordinate with MFM; consider ONSF if vision threatened.

— Patient with prior "sulfa rash" needs IIH treatment.

— Answer: Acetazolamide is generally tolerated; sulfonamide non-antibiotic class. Counsel and monitor; or use topiramate.

— IIH shunted patient now with orthostatic headache (worse upright).

— Answer: Low-pressure headache from shunt overdrainage; adjust programmable valve, not increase acetazolamide.

— 8-year-old, non-obese, started on growth hormone, develops papilledema.

— Answer: Stop GH (after endocrine discussion), workup, treat.

— Asymptomatic young patient with "blurred discs" found incidentally, no visual symptoms, normal fields.

— Answer: B-scan ultrasound or OCT — diagnose optic disc drusen, not IIH; no LP needed if exam consistent.

Step 3 management: On vignettes featuring an obese young woman with classic features, the highest-yield "next best step" almost always = MRI with MRV (not LP, not acetazolamide) — imaging precedes LP, and you must rule out CVST.

Classic vignette 1 — New diagnosis:

Classic vignette 2 — The drug trigger:

Classic vignette 3 — The MRV trap:

Classic vignette 4 — Fulminant IIH:

Classic vignette 5 — Pregnancy:

Classic vignette 6 — Sulfa allergy:

Classic vignette 7 — Shunt overdrainage:

Classic vignette 8 — Pediatric pre-pubertal IIH:

Classic vignette 9 — Disc drusen mimic:

One-Line Recap

Idiopathic intracranial hypertension is a syndrome of elevated ICP in obese women of childbearing age, diagnosed by Modified Dandy criteria (papilledema + normal imaging including MRV + opening pressure >250 mm H₂O + normal CSF), managed by weight loss and acetazolamide with surgical CSF diversion or optic nerve sheath fenestration reserved for vision-threatening disease — because vision, not headache, drives every escalation decision.

— Diagnosis: Always image before LP; MRV is mandatory to exclude CVST. Modified Dandy criteria are the framework — elevated OP, normal CSF, normal parenchymal imaging, no other cause.

— Treatment hierarchy: Weight loss (6–10%) is the only disease-modifying therapy; acetazolamide (IIHTT-proven) is first-line pharmacotherapy; topiramate adds migraine benefit but is teratogenic; VP shunt / ONSF / venous sinus stenting for refractory or fulminant disease.

— Monitoring spine: Serial automated perimetry + OCT RNFL by neuro-ophthalmology every 2–4 weeks initially, then every 1–3 months; BMP for acetazolamide-induced metabolic acidosis and hypokalemia; weight at every visit.

— Don't-miss pivots: Stop tetracyclines, retinoids, vitamin A, growth hormone triggers; rule out CVST, malignant HTN, dural AV fistula, optic neuritis, disc drusen; screen and treat OSA, anemia; counsel reproductive-age women on topiramate teratogenicity and acetazolamide use in pregnancy.

Board pearl: The most expensive errors on Step 3 IIH stems are (1) doing LP before imaging, (2) forgetting MRV and missing CVST, (3) under-escalating fulminant vision loss, and (4) omitting weight-loss counseling — get these four right and the topic is in hand.

High-yield recap bullets: